| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
178,600,000 |
| Market
Cap: |
242.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8901 - $1.85 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.4 |
| Insider 3/6 Months : 8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
96,686 |
1,592,031 |
13,134,243 |
| Total Buy Value |
$0 |
$136,327 |
$2,615,293 |
$22,822,494 |
| Total People Bought |
0 |
1 |
4 |
8 |
| Total Buy Transactions |
0 |
1 |
6 |
12 |
| Total Shares Sold |
0 |
96,686 |
455,706 |
505,706 |
| Total Sell Value |
$0 |
$136,327 |
$650,097 |
$765,097 |
| Total People Sold |
0 |
1 |
6 |
6 |
| Total Sell Transactions |
0 |
1 |
21 |
22 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shapiro Robert B |
Director |
– • – |
2019-03-08 |
4 |
A |
$5.06 |
$62,997 |
D/D |
12,450 |
59,594 |
|
- |
|
| Bostick Thomas |
Chief Operating Officer |
• – – |
2019-03-06 |
4 |
A |
$4.86 |
$10,085 |
D/D |
2,075 |
25,895 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2019-03-05 |
4 |
S |
$4.66 |
$10,718 |
I/I |
(2,300) |
41,705 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2019-03-04 |
4 |
S |
$4.17 |
$943,690 |
I/I |
(225,500) |
44,005 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2019-02-28 |
4 |
A |
$7.97 |
$199,999 |
I/I |
25,094 |
16,108,845 |
|
- |
|
| Alvarez Cesar L |
Director |
– • – |
2019-02-19 |
4 |
OE |
$3.17 |
$9,409 |
D/D |
2,968 |
117,817 |
|
- |
|
| Frank Steven |
Director |
– • – |
2019-02-12 |
4 |
OE |
$3.17 |
$9,409 |
D/D |
2,968 |
195,225 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2019-02-07 |
4 |
OE |
$3.17 |
$9,412 |
D/D |
2,969 |
96,280 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2019-01-31 |
4 |
A |
$7.66 |
$199,995 |
I/I |
26,109 |
16,083,751 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
I/I |
13,774 |
16,057,642 |
|
- |
|
| Sabzevari Helen |
President, Precigen, Inc. |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
36,306 |
|
- |
|
| Perez Jeffrey Thomas |
SVP, IP Affairs |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
32,563 |
|
- |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
47,957 |
|
- |
|
| Liffman Joel D |
SVP, Finance |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
99,315 |
|
- |
|
| Nimrodi Nir |
Chief Business Officer |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
19,482 |
|
- |
|
| Bostick Thomas |
Chief Operating Officer |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
23,820 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
93,311 |
|
- |
|
| Sterling Rick L. |
Chief Financial Officer |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
94,647 |
|
- |
|
| Walsh Robert F. Iii |
SVP, Energy & Fine Chem. |
• – – |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,774 |
19,482 |
|
- |
|
| Liffman Joel D |
SVP, Finance |
• – – |
2019-01-04 |
4 |
AS |
$7.03 |
$26,187 |
D/D |
(3,725) |
85,541 |
|
- |
|
| Perez Jeffrey Thomas |
SVP, IP Affairs |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$24,846 |
D/D |
(3,514) |
18,789 |
|
- |
|
| Sterling Rick L. |
Chief Financial Officer |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$24,846 |
D/D |
(3,514) |
80,873 |
|
- |
|
| Sabzevari Helen |
President, Precigen, Inc. |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$27,094 |
D/D |
(3,832) |
22,532 |
|
- |
|
| Walsh Robert F. Iii |
SVP, Energy & Fine Chem. |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$28,692 |
D/D |
(4,058) |
5,708 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$20,816 |
D/D |
(2,944) |
79,537 |
|
- |
|
689 Records found
|
|
Page 19 of 28 |
|
|
0.02 (1.49%) 
